Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Antidepressant effects of ketamine in depressed patients.

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH.

Biol Psychiatry. 2000 Feb 15;47(4):351-4.

PMID:
10686270
2.

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK.

Arch Gen Psychiatry. 2006 Aug;63(8):856-64.

PMID:
16894061
3.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
4.

Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.

Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH.

Psychiatry Res. 2014 Feb 28;215(2):355-61. doi: 10.1016/j.psychres.2013.12.008. Epub 2013 Dec 13.

PMID:
24374115
5.

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr.

J Clin Psychiatry. 2009 Dec;70(12):1662-6. doi: 10.4088/JCP.08m04659. Epub 2009 Sep 8.

6.

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ.

Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.

7.

Intravenous ketamine therapy in a patient with a treatment-resistant major depression.

Liebrenz M, Borgeat A, Leisinger R, Stohler R.

Swiss Med Wkly. 2007 Apr 21;137(15-16):234-6.

PMID:
17525879
8.

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.

Paul R, Schaaff N, Padberg F, Möller HJ, Frodl T.

World J Biol Psychiatry. 2009;10(3):241-4. doi: 10.1080/15622970701714370.

PMID:
19224412
9.

Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.

Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments.

Am J Psychiatry. 2015 Oct;172(10):950-66. doi: 10.1176/appi.ajp.2015.15040465. Review.

PMID:
26423481
10.

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA.

Biol Psychiatry. 2013 Aug 15;74(4):257-64. doi: 10.1016/j.biopsych.2012.10.019. Epub 2012 Dec 1.

11.

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr.

J Clin Psychiatry. 2010 Dec;71(12):1605-11. doi: 10.4088/JCP.09m05327blu. Epub 2010 Jul 13.

12.

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

Luckenbaugh DA, Ibrahim L, Brutsche N, Franco-Chaves J, Mathews D, Marquardt CA, Cassarly C, Zarate CA Jr.

Bipolar Disord. 2012 Dec;14(8):880-7. doi: 10.1111/bdi.12003. Epub 2012 Sep 14.

13.

Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.

Luckenbaugh DA, Ameli R, Brutsche NE, Zarate CA Jr.

J Psychiatr Res. 2015 Feb;61:40-5. doi: 10.1016/j.jpsychires.2014.12.015. Epub 2014 Dec 27.

14.

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH.

Arch Gen Psychiatry. 2000 Mar;57(3):270-6.

PMID:
10711913
15.

Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.

Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, Brutsche NE, Zarate CA Jr.

J Clin Psychiatry. 2014 Sep;75(9):e932-8. doi: 10.4088/JCP.14m09049.

PMID:
25295436
16.

Ketamine and other potential glutamate antidepressants.

Dutta A, McKie S, Deakin JF.

Psychiatry Res. 2015 Jan 30;225(1-2):1-13. doi: 10.1016/j.psychres.2014.10.028. Epub 2014 Nov 13. Review.

PMID:
25467702
17.

Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.

Duncan WC Jr, Selter J, Brutsche N, Sarasso S, Zarate CA Jr.

J Affect Disord. 2013 Feb 15;145(1):115-9. doi: 10.1016/j.jad.2012.05.042. Epub 2012 Aug 5.

18.

Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.

Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM; GLYX-13 Clinical Study Group.

J Psychiatr Pract. 2015 Mar;21(2):140-9. doi: 10.1097/01.pra.0000462606.17725.93.

PMID:
25782764
19.

[Ketamine for treatment of acute depression].

Hjerrild S, Bjerre J, Pedersen RH, Videbech P.

Ugeskr Laeger. 2013 Sep 9;175(37):2090-3. Review. Danish.

PMID:
24011203
20.

Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.

Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T.

Neuro Endocrinol Lett. 2013;34(4):287-93.

PMID:
23803871

Supplemental Content

Support Center